CAR T cells in skin cancer: From experimental promise to clinical translation
Cellular therapy is entering a new phase in solid tumors. For dermato-oncology, this shift is no longer theoretical: tumor-infiltrating lymphocyte (TIL) therapy is approved in the United States, and PRAME-directed T cell receptor (TCR) T cells provide the leading receptor-defined benchmark for melanoma. Chimeric antigen receptor (CAR) T cell therapy has entered early-phase clinical evaluation for melanoma and cutaneous lymphomas, with ongoing trials targeting GD2, IL13Rα2, NG2, DLL3, and CD30. Early clinical findings support the feasibility of this approach, demonstrate CAR T cell trafficking to tumor sites, and indicate an acceptable safety profile. The clinical challenge is therefore not conceptual but translational: selecting sufficiently tumor-restricted surface antigens, overcoming antigen heterogeneity, improving trafficking and persistence, and combining CAR T cells rationally with checkpoint blockade, targeted therapy, radiotherapy, or oncolytic strategies. This article summarizes the current clinical landscape and proposes a practical path toward biomarker-selected, combination-ready CAR T cell trials in advanced skin cancer.
Authors
- Uğur Uslu (ORCID: https://orcid.org/0000-0001-8109-7892)
Institutions
- Universitätsklinikum Würzburg (DE)
Publication Details
- Journal
- JDDG Journal der Deutschen Dermatologischen Gesellschaft
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1111/ddg.70578
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00